Cargando…

Simvastatin suppresses dexamethasone-induced secretion of plasminogen activator inhibitor-1 in human bone marrow adipocytes

BACKGROUND: Osteonecrosis of the femoral head is a common complication of high-dose glucocorticoid treatment. Intravascular thrombosis is thought to be associated with the ischemic state of the femoral head. Plasminogen activator inhibitor-1 (PAI-1) is an adipokine, which are physiologically active...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakamoto, Kazutaka, Osaki, Makoto, Hozumi, Akira, Goto, Hisataka, Fukushima, Tatsuya, Baba, Hideo, Shindo, Hiroyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3114799/
https://www.ncbi.nlm.nih.gov/pubmed/21524281
http://dx.doi.org/10.1186/1471-2474-12-82
_version_ 1782206115959799808
author Sakamoto, Kazutaka
Osaki, Makoto
Hozumi, Akira
Goto, Hisataka
Fukushima, Tatsuya
Baba, Hideo
Shindo, Hiroyuki
author_facet Sakamoto, Kazutaka
Osaki, Makoto
Hozumi, Akira
Goto, Hisataka
Fukushima, Tatsuya
Baba, Hideo
Shindo, Hiroyuki
author_sort Sakamoto, Kazutaka
collection PubMed
description BACKGROUND: Osteonecrosis of the femoral head is a common complication of high-dose glucocorticoid treatment. Intravascular thrombosis is thought to be associated with the ischemic state of the femoral head. Plasminogen activator inhibitor-1 (PAI-1) is an adipokine, which are physiologically active substances secreted from visceral and subcutaneous adipocytes. PAI-1 suppresses fibrinolysis by binding tissue-type plasminogen activator. Several reports have described the relationship between PAI-1 and steroid-induced osteonecrosis of the femoral head, and the preventive effects of lipid-lowering agents (statins) against steroid-induced osteonecrosis of the femoral head. We previously reported that adipokines and dexamethasone induced PAI-1 secretion from bone marrow adipocytes. The purpose of the present study is to examine the effects of simvastatin on PAI-1 secretion from human bone marrow adipocytes in vitro. METHODS: Primary bone marrow adipocytes were extracted from collagenase-treated bone marrow fluid obtained from the femoral necks of 40 patients (6 men, 34 women; age range, 52-81 years) undergoing hip joint replacement surgery. After suspended culture with or without dexamethasone or simvastatin, PAI-1 mRNA expression was assessed by real-time RT-PCR. Total PAI-1 protein secretion in culture medium was assessed by enzyme-linked immunosorbent assay. RESULTS: PAI-1 mRNA expression was up-regulated by 388% (P = 0.002) with dexamethasone, and down-regulated by 45% (P = 0.002) with simvastatin, as compared to control levels. Dexamethasone increased total PAI-1 secretion by 166% (P = 0.001) and simvastatin decreased total PAI-1 secretion by 64% (P = 0.002). No significant changes were observed in adiponectin mRNA expression and secretion by dexamethasone and simvastatin, while pre-treatment with simvastatin reversed dexamethasone induced PAI-1 secretion by 89%, as compared to control levels. CONCLUSION: The present study confirmed the suppressive effects of simvastatin on PAI-1 expression and secretion from bone marrow adipocytes. Furthermore, pre-treatment with simvastatin reversed dexamethasone induced PAI-1 secretion. Simvastatin may thus exhibit preventive effects against steroid-induced osteonecrosis of the femoral head by suppressing PAI-1 secretion.
format Online
Article
Text
id pubmed-3114799
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-31147992011-06-15 Simvastatin suppresses dexamethasone-induced secretion of plasminogen activator inhibitor-1 in human bone marrow adipocytes Sakamoto, Kazutaka Osaki, Makoto Hozumi, Akira Goto, Hisataka Fukushima, Tatsuya Baba, Hideo Shindo, Hiroyuki BMC Musculoskelet Disord Research Article BACKGROUND: Osteonecrosis of the femoral head is a common complication of high-dose glucocorticoid treatment. Intravascular thrombosis is thought to be associated with the ischemic state of the femoral head. Plasminogen activator inhibitor-1 (PAI-1) is an adipokine, which are physiologically active substances secreted from visceral and subcutaneous adipocytes. PAI-1 suppresses fibrinolysis by binding tissue-type plasminogen activator. Several reports have described the relationship between PAI-1 and steroid-induced osteonecrosis of the femoral head, and the preventive effects of lipid-lowering agents (statins) against steroid-induced osteonecrosis of the femoral head. We previously reported that adipokines and dexamethasone induced PAI-1 secretion from bone marrow adipocytes. The purpose of the present study is to examine the effects of simvastatin on PAI-1 secretion from human bone marrow adipocytes in vitro. METHODS: Primary bone marrow adipocytes were extracted from collagenase-treated bone marrow fluid obtained from the femoral necks of 40 patients (6 men, 34 women; age range, 52-81 years) undergoing hip joint replacement surgery. After suspended culture with or without dexamethasone or simvastatin, PAI-1 mRNA expression was assessed by real-time RT-PCR. Total PAI-1 protein secretion in culture medium was assessed by enzyme-linked immunosorbent assay. RESULTS: PAI-1 mRNA expression was up-regulated by 388% (P = 0.002) with dexamethasone, and down-regulated by 45% (P = 0.002) with simvastatin, as compared to control levels. Dexamethasone increased total PAI-1 secretion by 166% (P = 0.001) and simvastatin decreased total PAI-1 secretion by 64% (P = 0.002). No significant changes were observed in adiponectin mRNA expression and secretion by dexamethasone and simvastatin, while pre-treatment with simvastatin reversed dexamethasone induced PAI-1 secretion by 89%, as compared to control levels. CONCLUSION: The present study confirmed the suppressive effects of simvastatin on PAI-1 expression and secretion from bone marrow adipocytes. Furthermore, pre-treatment with simvastatin reversed dexamethasone induced PAI-1 secretion. Simvastatin may thus exhibit preventive effects against steroid-induced osteonecrosis of the femoral head by suppressing PAI-1 secretion. BioMed Central 2011-04-27 /pmc/articles/PMC3114799/ /pubmed/21524281 http://dx.doi.org/10.1186/1471-2474-12-82 Text en Copyright ©2011 Sakamoto et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Sakamoto, Kazutaka
Osaki, Makoto
Hozumi, Akira
Goto, Hisataka
Fukushima, Tatsuya
Baba, Hideo
Shindo, Hiroyuki
Simvastatin suppresses dexamethasone-induced secretion of plasminogen activator inhibitor-1 in human bone marrow adipocytes
title Simvastatin suppresses dexamethasone-induced secretion of plasminogen activator inhibitor-1 in human bone marrow adipocytes
title_full Simvastatin suppresses dexamethasone-induced secretion of plasminogen activator inhibitor-1 in human bone marrow adipocytes
title_fullStr Simvastatin suppresses dexamethasone-induced secretion of plasminogen activator inhibitor-1 in human bone marrow adipocytes
title_full_unstemmed Simvastatin suppresses dexamethasone-induced secretion of plasminogen activator inhibitor-1 in human bone marrow adipocytes
title_short Simvastatin suppresses dexamethasone-induced secretion of plasminogen activator inhibitor-1 in human bone marrow adipocytes
title_sort simvastatin suppresses dexamethasone-induced secretion of plasminogen activator inhibitor-1 in human bone marrow adipocytes
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3114799/
https://www.ncbi.nlm.nih.gov/pubmed/21524281
http://dx.doi.org/10.1186/1471-2474-12-82
work_keys_str_mv AT sakamotokazutaka simvastatinsuppressesdexamethasoneinducedsecretionofplasminogenactivatorinhibitor1inhumanbonemarrowadipocytes
AT osakimakoto simvastatinsuppressesdexamethasoneinducedsecretionofplasminogenactivatorinhibitor1inhumanbonemarrowadipocytes
AT hozumiakira simvastatinsuppressesdexamethasoneinducedsecretionofplasminogenactivatorinhibitor1inhumanbonemarrowadipocytes
AT gotohisataka simvastatinsuppressesdexamethasoneinducedsecretionofplasminogenactivatorinhibitor1inhumanbonemarrowadipocytes
AT fukushimatatsuya simvastatinsuppressesdexamethasoneinducedsecretionofplasminogenactivatorinhibitor1inhumanbonemarrowadipocytes
AT babahideo simvastatinsuppressesdexamethasoneinducedsecretionofplasminogenactivatorinhibitor1inhumanbonemarrowadipocytes
AT shindohiroyuki simvastatinsuppressesdexamethasoneinducedsecretionofplasminogenactivatorinhibitor1inhumanbonemarrowadipocytes